Search

Your search keyword '"De Menis, E"' showing total 200 results
Start Over Author "De Menis, E"
200 results on '"De Menis, E"'

1. Disease control of acromegaly does not prevent excess mortality in the long term: results of a nationwide survey in Italy

Author

Arosio, M., Sciannameo, V., Contarino, A., Berchialla, P., Puglisi, S., Pesatori, A. C., Ferrante, E., Filopanti, M., Pivonello, R., Dassie, F., Rochira, V., Cannavò, S., De Menis, E., Pigliaru, F., Grottoli, S., Cambria, V., Faustini-Fustini, M., Montini, M., Peri, A., Ceccato, F., Puxeddu, E., Borretta, G., Bondanelli, M., Ferone, D., Colao, A., Terzolo, M., and Reimondo, G.

Published
2024
Full Text
View/download PDF

2. A pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas

Author

Basile, M, Valentini, Ilaria, Attanasio, R, Cozzi, R, Persichetti, A, Samperi, I, Scoppola, A, Auriemma, R, De Menis, E, Esposito, F, Ferrante, E, Iatì, G, Mazzatenta, D, Poggi, M, Rudà, R, Tortora, F, Cruciani, F, Mitrova, Z, Saulle, R, Vecchi, S, Cappabianca, P, Paoletta, A, Bozzao, A, Caputo, M, Doglietto, F, Ferraù, F, Lania, Ag, Laureti, S, Lello, S, Locatelli, D, Maffei, P, Minniti, G, Peri, A, Ruini, C, Settanni, F, Silvani, A, Veronese, N, Grimaldi, F, Papini, E, Cicchetti, A, Valentini, I (ORCID:0000-0001-5940-7495), Basile, M, Valentini, Ilaria, Attanasio, R, Cozzi, R, Persichetti, A, Samperi, I, Scoppola, A, Auriemma, R, De Menis, E, Esposito, F, Ferrante, E, Iatì, G, Mazzatenta, D, Poggi, M, Rudà, R, Tortora, F, Cruciani, F, Mitrova, Z, Saulle, R, Vecchi, S, Cappabianca, P, Paoletta, A, Bozzao, A, Caputo, M, Doglietto, F, Ferraù, F, Lania, Ag, Laureti, S, Lello, S, Locatelli, D, Maffei, P, Minniti, G, Peri, A, Ruini, C, Settanni, F, Silvani, A, Veronese, N, Grimaldi, F, Papini, E, Cicchetti, A, and Valentini, I (ORCID:0000-0001-5940-7495)

Abstract

Background: Prolactinoma, the most common pituitary adenoma, is usually treated with dopamine agonist (DA) therapy like cabergoline. Surgery is second-line therapy, and radiotherapy is used if surgical treatment fails or in relapsing macroprolactinoma. Objective: This study aimed to provide economic evidence for the management of prolactinoma in Italy, using a cost-of-illness and cost-utility analysis that considered various treatment options, including cabergoline, bromocriptine, temozolomide, radiation therapy, and surgical strategies. Methods: The researchers conducted a systematic literature review for each research question on scientific data- bases and surveyed a panel of experts for each therapeutic procedure's specific drivers that contributed to its total cost. Results: The average cost of the first year of treatment was euro2,558.91 and euro3,287.40 for subjects with micro- prolactinoma and macroprolactinoma, respectively. Follow-up costs from the second to the fifth year after ini- tial treatment were euro798.13 and euro1,084.59 per year in both groups. Cabergoline had an adequate cost-utility profile, with an incremental cost-effectiveness ratio (ICER) of euro3,201.15 compared to bromocriptine, based on a willingness-to-pay of euro40,000 per quality-adjusted life year (QALY) in the reference economy. Endoscopic sur- gery was more cost-effective than cabergoline, with an ICER of euro44,846.64. Considering a willingness-to-pay of euro40,000/QALY, the baseline findings show cabergoline to have high cost utility and endoscopic surgery just a tad above that. Conclusions: Due to the favorable cost-utility profile and safety of surgical treatment, pituitary surgery should be considered more frequently as the initial therapeutic approach. This management choice could lead to better outcomes and an appropriate allocation of healthcare resources.

Published
2024

3. Italian Guidelines for the Management of Prolactinomas

Author

Cozzi, R., Auriemma, R. S., De Menis, E., Esposito, F., Ferrante, E., Iati, G., Mazzatenta, D., Poggi, M., Ruda, R., Tortora, F., Cruciani, F., Mitrova, Z., Saulle, R., Vecchi, S., Basile, M., Cappabianca, P., Paoletta, A., Papini, E., Persichetti, A., Samperi, I., Scoppola, A., Bozzao, A., Caputo, M., Doglietto, Francesco, Ferrau, F., Lania, A. G., Laureti, S., Lello, S., Locatelli, D., Maffei, P., Minniti, G., Peri, A., Ruini, C., Settanni, F., Silvani, A., Veronese, N., Grimaldi, F., Attanasio, R., Doglietto F. (ORCID:0000-0002-7438-0734), Cozzi, R., Auriemma, R. S., De Menis, E., Esposito, F., Ferrante, E., Iati, G., Mazzatenta, D., Poggi, M., Ruda, R., Tortora, F., Cruciani, F., Mitrova, Z., Saulle, R., Vecchi, S., Basile, M., Cappabianca, P., Paoletta, A., Papini, E., Persichetti, A., Samperi, I., Scoppola, A., Bozzao, A., Caputo, M., Doglietto, Francesco, Ferrau, F., Lania, A. G., Laureti, S., Lello, S., Locatelli, D., Maffei, P., Minniti, G., Peri, A., Ruini, C., Settanni, F., Silvani, A., Veronese, N., Grimaldi, F., Attanasio, R., and Doglietto F. (ORCID:0000-0002-7438-0734)

Abstract

Introduction: This guideline (GL) is aimed at providing a reference for the management of prolactin (PRL)-secreting pituitary adenoma in adults. However, pregnancy is not considered. Methods: This GL has been developed following the methods described in the Manual of the Italian National Guideline System. For each question, the panel appointed by Associazione Medici Endocrinologi (AME) has identified potentially relevant outcomes, which have then been rated for their impact on therapeutic choices. Only outcomes classified as “critical” and “important” have been considered in the systematic review of evidence and only those classified as “critical” have been considered in the formulation of recommendations. Results: The present GL provides recommendations regarding the role of pharmacological and neurosurgical treatment in the management of prolactinomas. We recommend cabergoline (Cab) vs. bromocriptine (Br) as the first-choice pharmacological treatment to be employed at the minimal effective dose capable of achieving the regression of the clinical picture. We suggest that medication and surgery are offered as suitable alternative first-line treatments to patients with non-invasive PRL-secreting adenoma, regardless of size. We suggest Br as an alternative drug in patients who are intolerant to Cab and are not candidates for surgery. We recommend pituitary tumor resection in patients 1) without any significant neuro-ophthalmologic improvement within two weeks from the start of Cab, 2) who are resistant or do not tolerate Cab or other dopamine-agonist drugs (DA), 3) who escape from previous efficacy of DA, and 4) who are unwilling to undergo a chronic DA treatment. We recommend that patients with progressive disease notwithstanding previous tumor resection and ongoing DA should be managed by a multidisciplinary team with specific expertise in pituitary diseases using a multimodal approach that includes repeated surgery, radiother-apy, DA, and possibly, the use of temoz

Published
2023

4. Pegvisomant in acromegaly: an update

Author

Giustina, A., Arnaldi, G., Bogazzi, F., Cannavò, S., Colao, A., De Marinis, L., De Menis, E., Degli Uberti, E., Giorgino, F., Grottoli, S., Lania, A. G., Maffei, P., Pivonello, R., and Ghigo, E.

Published
2017
Full Text
View/download PDF

7. Position statement for clinical practice: prolactin-secreting tumors

Author

Cozzi, R, Ambrosio, Mr, Attanasio, R, Battista, C, Bozzao, A, Caputo, M, Ciccarelli, E, De Marinis, L, De Menis, E, Faustini Fustini, M, Grimaldi, F, Lania, A, Lasio, G, Logoluso, F, Losa, M, Maffei, P, Milani, D, Poggi, M, Zini, M, Katznelson, L, Luger, A, and Poiana, C.

Published
2022

16. Pegvisomant in acromegaly: Why, when, how

Author

Colao, A., Arnaldi, G., Beck-Peccoz, P., Cannavò, S., Cozzi, R., degli Uberti, E., De Marinis, L., De Menis, E., Ferone, D., Gasco, V., Giustina, A., Grottoli, S., Lombardi, G., Maffei, P., Martino, E., Minuto, F., Pivonello, R., and Ghigo, E.

Published
2007
Full Text
View/download PDF

20. Correction to: Pegvisomant in acromegaly: an update (Journal of Endocrinological Investigation, (2017), 40, 6, (577-589), 10.1007/s40618-017-0614-1)

Author

Giustina, A., Arnaldi, G., Bogazzi, F., Cannavò, S., Colao, A., De Marinis, L., De Menis, E., Degli Uberti, E., Giorgino, F., Grottoli, S., Lania, A. G., Maffei, P., Pivonello, R., Ghigo, E., Giustina, A., Arnaldi, G., Bogazzi, F., Cannavò, S., Colao, A., De Marinis, L., De Menis, E., Degli Uberti, E., Giorgino, F., Grottoli, S., Lania, A. G., Maffei, P., Pivonello, R., and Ghigo, E.

Subjects
Endocrinology, Endocrinology, Diabetes and Metabolism
Published
2018

24. Clinical Characterization of Familial Isolated Pituitary Adenomas

Author

Daly, A F., Jaffrain-Rea, M -L., Ciccarelli, A, Valdes-Socin, H, Rohmer, V, Tamburrano, G, Borson-Chazot, C, Estour, B, Ciccarelli, E, Brue, T, Ferolla, P, Emy, P, Colao, A, De Menis, E, Lecomte, P, Penfornis, F, Delemer, B, Bertherat, J, Wémeau, J L., De Herder, W, Archambeaud, F, Stevenaert, A, Calender, A, Murat, A, Cavagnini, F, and Beckers, A

Published
2006

28. Predittori di morbilità e mortalità nell’acromegalia: studio italiano del Gruppo di Studio sull’Acromegalia

Author

Arosio, M., Reimondo, G., Malchiodi, E., Berchialla, P., Borraccino, A., De Marinis, L., Oivonello, R., Grotoli, S., Losa, M., Cannavò, S., Minuto, F., Montini, M., Bondanelli, M., De Menis, E., Martini, C., Angeletti, G., Velardo, A., Peri, A., Faustini-Fustini, M., Tita, P., Pigliaru, F., Borretta, G., Scaroni, C., Bazzoni, N., Bianchi, A., Appetecchia, M., Cavagnini, F., Lombardi, G., Ghigo, E., Peccoz, P. Peck, Colao, A., Terzolo, M., Arvat, Emanuela, and Gruppo di Studio Italiano sull’Acromegalia

Published
2012
Full Text
View/download PDF

30. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Educcation) Studi Group

Author

COLAO A, MARTINO E, CAPPABIANCA P, COZZI R, SCANARINI M, GHIGO E, ANGELETTI G, ANILE C, ARNALDI G, AROSIO M, ATTANASIO R, AURIEMMA R, BALDELLI R, BILLECI D, BORRETTA G, BOSCARO M, CANNAV0' S, CAVAGNINI F, D'ARRIGO C, D'AZZO G, DE MARINIS L, DE MENIS E, DEGLI UBERTI E, ESPOSITO F, FERONE D, FORMOSO G, GASCO V, GASPERI M, GIORDANO E, GIUSTINA A, GROTTOLI S, LA NOTTE M, LASIO G, LOMBARDI G, LOSA M, MANTERO F, MARIOTTI S, MARZULLO P, MAZZATENTA D, MINUTO F, MONTINI M, PACINI F, PEZZINO V, PIVONELLO R, RONCHI C, SICOLO N, SINISI A, SPADA A, TAMBURRANO G, TERZOLO M, TITA PMB, VIGO MT, CIRILLO, Sossio, Colao, A, Martino, E, Cappabianca, P, Cozzi, R, Scanarini, M, Ghigo, E, Angeletti, G, Anile, C, Arnaldi, G, Arosio, M, Attanasio, R, Auriemma, R, Baldelli, R, Billeci, D, Borretta, G, Boscaro, M, Cannav0', S, Cavagnini, F, Cirillo, Sossio, D'Arrigo, C, D'Azzo, G, DE MARINIS, L, DE MENIS, E, DEGLI UBERTI, E, Esposito, F, Ferone, D, Formoso, G, Gasco, V, Gasperi, M, Giordano, E, Giustina, A, Grottoli, S, LA NOTTE, M, Lasio, G, Lombardi, G, Losa, M, Mantero, F, Mariotti, S, Marzullo, P, Mazzatenta, D, Minuto, F, Montini, M, Pacini, F, Pezzino, V, Pivonello, R, Ronchi, C, Sicolo, N, Sinisi, A, Spada, A, Tamburrano, G, Terzolo, M, Tita, Pmb, and Vigo, Mt

Published
2006

31. A multicenter experience on the prevalence of ARMC5 mutations in patients with primary bilateral macronodular adrenal hyperplasia: from genetic characterization to clinical phenotype

Author

Albiger, N. M., primary, Regazzo, D., additional, Rubin, B., additional, Ferrara, A. M., additional, Rizzati, S., additional, Taschin, E., additional, Ceccato, F., additional, Arnaldi, G., additional, Pecori Giraldi, F., additional, Stigliano, A., additional, Cerquetti, L., additional, Grimaldi, F., additional, De Menis, E., additional, Boscaro, M., additional, Iacobone, M., additional, Occhi, G., additional, and Scaroni, C., additional

Published
2016
Full Text
View/download PDF

32. Growth hormone-releasing hormone resistance in pseudohypoparathyroidism type ia: new evidence for imprinting of the Gs alpha gene

Author

Mantovani, G, Maghnie, Mohamad, Weber, G, DE MENIS, E, Brunelli, V, Cappa, M, Loli, P, BECK PECCOZ, P, Spada, A., Mantovani, G, Maghnie, M, Weber, Giovanna, DE MENIS, E, Brunelli, V, Cappa, M, Loli, P, BECK PECCOZ, P, and Spada, A.

Abstract

Heterozygous inactivating mutations in the Gs alpha gene cause Albright's hereditary osteodystrophy. Consistent with the observation that only maternally inherited mutations lead to resistance to hormone action [pseudohypoparathyroidism type Ia (PHP Ia)], recent studies provided evidence for a predominant maternal origin of Gs alpha transcripts in endocrine organs, such as thyroid, gonad, and pituitary. The aim of this study was to investigate the presence of pituitary resistance to hypothalamic hormones acting via Gs alpha-coupled receptors in patients with PHP Ia. Six of nine patients showed an impaired GH responsiveness to GHRH plus arginine, consistent with a complete GH deficiency (GH peak from 2.6-8.6 microg/liter, normal > 16.5), and partial (GH peak 13.9 and 13.6 microg/liter) and normal responses were found in two and one patient, respectively. Accordingly, IGF-I levels were below and in the low-normal range in seven and two patients. All patients had a normal cortisol response to 1 microg ACTH test, suggesting a normal corticotroph function that was confirmed by a normal ACTH and cortisol response to CRH test in three patients. In conclusion, we report that in addition to PTH and TSH resistance, patients with PHP Ia display variable degrees of GHRH resistance, consistent with Gs alpha imprinting in human pituitary

Published
2003

34. The R304X mutation of the Aryl hydrocarbon receptor Interacting Protein (AIP) gene in familial isolated pituitary adenomas: mutational Hot-Spot or founder effect?

Author

Occhi, G, Jaffrain, MARIE LISE, Trivellin, G, Albiger, N, Ceccato, F, DE MENIS, E, Angelini, M, Ferasin, S, Mantero, F, Beckers, A, and Scaroni, C.

Subjects
Pituitary adenomas, familial pituitary adenomas, genetics, Aryl hydrocarbon receptor Interacting Protein (AIP), familial pituitary adenomas, genetics, Aryl hydrocarbon receptor Interacting Protein (AIP), Pituitary adenomas
Published
2010

36. Familial isolated pituitary adenomas

Author

Daly, A.F., Jaffrain-Rea, M.L., Ciccarelli, E., Brue, Thierry, Ferolla, P., Emy, P., Colao, A., de Menis, E., Lecompte, P., Penfornis, F., Delemer, B., Bertherat, J., Wemeau, J.L., de Herder, W., Archambeaud, F., Stevenaert, A., Calender, A., Murat, François, Beckers, A., Gautron, Conception, Interactions cellulaires neuroendocriniennes (ICN), and Université de la Méditerranée - Aix-Marseille 2-Centre National de la Recherche Scientifique (CNRS)

Published
2006

40. Hypopituitarism and growth hormone deficinecy

Author

Aimaretti, G, Ambrosio, Mr, Benvenga, Salvatore, Borretta, G, DE MARINIS, L, DE MENIS, E, DI SOMMA, C, FAUSTINI FUSTINI, M, Grottoli, S, Gasco, V, Gasperi, M, Logoluso, F, Scaroni, C, Giordano, G, and Ghigo, E.

Published
2004

44. Clinical presentation and outcome of pituitary adenomas in teenagers

Author

Cannavo', Salvatore, Venturino, M, Curto', L, DE MENIS, E, D'Arrigo, C, Tita, P, Billeci, D, and Trimarchi, Francesco

Subjects
Adenoma, Adult, Male, Puberty, Delayed, Adolescent, Pituitary Function Tests, Headache, Magnetic Resonance Imaging, Adrenocorticotropic Hormone, Growth Hormone, Humans, Female, Pituitary Neoplasms, Prolactinoma, Child, Tomography, X-Ray Computed, Menstruation Disturbances, Retrospective Studies
Abstract

Pituitary adenomas rarely occur in childhood and adolescence, but their mass effect and endocrine abnormalities can compromise both quality and length of life. In this study we evaluated the symptoms at onset and the long-term consequences induced in teenagers by functioning or nonfunctioning pituitary adenomas.Clinical, biochemical and neuroradiological data of 44 young patients (12 males and 32 females, aged 16.3 +/- 1.9 years at diagnosis) with pituitary adenomas were evaluated retrospectively at baseline and after therapy. Patients underwent surgery, radiotherapy and/or medical treatment depending on clinical history and endocrine secretion of the tumour. Follow-up ranged from 8 to 252 months (median 55 months).Baseline and dynamic pituitary function were evaluated in all cases at diagnosis and after treatments. Magnetic resonance imaging (MRI) or computed tomography (CT) scan were performed before therapy and during follow-up. Hormone levels were measured using commercial radioimmunologic or immunoradiometric methods.Pituitary macroadenomas (group 1) or microadenomas (group 2) were found in 61% and 39% of cases, respectively. Overall, 68% were PRL-secreting, 7% GH-secreting, 5% ACTH-secreting and 20% nonfunctioning. The most frequent symptoms at onset were oligoamenorrhoea (62%) and galactorrhoea (59%) in the girls, and headache (58%) in the boys. Pubertal development was delayed in 12/27 (44%) cases with macroadenoma. Growth failure was observed in 4/44 (9%) patients (3 in group 1 and 1 in group 2). At diagnosis, hypopituitarism was detected in 10/27 (37%) patients with macroadenoma. Surgery alone cured 4/18 (22%) and 4/9 (44%) patients in group 1 and group 2, respectively. Adjuvant therapies (second surgery and/or radiotherapy and/or medical treatment) cured the disease in 2/13 (15%) patients with macroadenoma and allowed a persistent normalization in other 4/13 (31%) and 2/4 (50%) cases in group 1 and group 2, respectively. Medical treatment alone cured 2/9 (22%) patients with PRL-secreting macroadenoma and normalized PRL levels in another six (66%) with macroprolactinoma and in 2/7 (28%) patients with microprolactinoma.Delay of growth was rarely observed in teenagers with pituitary adenomas. At the onset of the disease, many girls complained of oligoamenorrhoea and galactorrhoea, while headache and delay of pubertal development were the symptoms more frequently referred by boys. Surgery alone was effective in a minority of patients and adjuvant therapies were helpful to obtain the remission of the disease in many cases. In patients with PRL-secreting pituitary adenoma, medical treatment, both as first choice or as adjuvant therapy, normalizes serum PRL levels in 14/27 (52%) cases.

Published
2003

47. Adrenal tumors in acromegaly

Author

Selice, R., Scaroni, Carla, DE MENIS, E., Arosio, M., Ronchi, C., Gasperi, M., Manetti, L., Arnaldi, G., Polenta, B., Motta, R. G., Boscaro, Marco, and Mantero, Franco

Published
2003

49. Octretide LAR in patients with newly diagnosed acromegaly

Author

Colao, A., Ghigo, E., Rosato, F., DEGLI UBERTI, E., Sicolo, N., DE MENIS, E., Mariotti, S., Martino, E., BECK PECCOZ, P., Minuto, F., Tamburrano, G., Pezzino, V., Pagani, G., Loli, P., Barreca, A., Ferrara, R., Alberti, D., and Angeletti, Gabriella

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results